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Introduction

Apixaban (Eliquis
Ò
; Bristol-Myers Squibb, Princeton, NJ, USA) is one of several oral direct factor Xa (FXa) inhibitors and is approved in several countries, including the United States and Europe, for the prevention and treatment of various thrombotic conditions [1, 2] .
As with vitamin K antagonists (VKAs), reversal of anticoagulation induced by newer oral anticoagulants (NOACs) such as apixaban may be necessary in bleeding patients or in those requiring urgent surgery. Guidelines suggest the use of recombinant activated FVII (rFVIIa) or activated/non-activated prothrombin complex concentrates (aPCCs/PCCs) [3] [4] [5] . However, validated NOAC reversal strategies are lacking, although antidotes for FXa inhibitors are currently in development [6] . Though there have been several studies of NOAC reversal in healthy volunteers [7] [8] [9] , real-world data regarding management of NOAC-related major bleeding are scarce. Observations suggest that traditional coagulation assays may not be predictive of the ability of prohemostatic agents to stop bleeding [10] , adding to the complexity of patient management in time-critical situations.
Reversal of the anticoagulant effects of dabigatran, edoxaban, and rivaroxaban by a non-activated fourfactor PCC (4F-PCC) has been demonstrated in an in vivo rabbit model of acute bleeding [11] [12] [13] . The aims of this study are to evaluate the ability of the same 4F-PCC to reverse the anticoagulant effects of apixaban in this model and to investigate correlations between in vitro coagulation parameters and in vivo measures of hemostasis.
Materials and methods
Study design
This open-label study was conducted using a previously described rabbit model [11] [12] [13] ; a brief description of study design and methods is provided next. Study animals received care in compliance with the European Convention on Animal Care, and procedures were approved by the local animal welfare authority.
The primary endpoint was the ability of 4F-PCC to reverse the effects of apixaban on time to hemostasis and volume of blood loss. Coagulation parameters were also assessed, including prothrombin time (PT), activated partial thromboplastin time (aPTT), whole blood clotting time (WBCT) [14] , and thrombin generation (TG), following either extrinsic activation using phospholipids and tissue factor (5 pmol L -1 ), or intrinsic activation using phospholipids only (RD reagent). Apixaban plasma levels were measured via the FXa inhibition assay, as previously described [12, 13] .
Study agents
4F-PCC (Beriplex
; CSL Behring GmbH, Marburg, Germany), containing FII, FVII, FIX, FX, and coagulation proteins C and S [15] , was reconstituted as per label. Apixaban (kindly provided by Bristol-Myers Squibb, Plainsboro, NJ, USA) was reconstituted in a vehicle solution of dimethylacetamide:propanediol:water (10%:20%:70%) to a concentration of 0.5 mg mL
À1
.
Treatment
Treatment group assignments are shown in Table 1 . In the dose-finding part of the study, anesthetized animals received a single intravenous (i.v.) administration of either reconstituted apixaban or vehicle solution followed 3 min later by an i.v. bolus of 0.9% (w/v) isotonic saline.
For the subsequent reversal study phase, anesthetized animals were randomized to receive an i.v. administration of reconstituted apixaban (1200 lg kg
À1
; t = 0) followed by an i.v. bolus of 4F-PCC (6.25, 12.5, 25, 50, 75, or 100 IU kg À1 ; t = 3 min). Sample sizes were based on previous experience of NOAC reversal in this rabbit model. In both parts of the study, at t = 8 min a standardized kidney incision was created as described previously [12] . The 30-min observation period for the assessment of blood loss and time to hemostasis began immediately after the incision. Blood loss was measured as the volume of blood collected by syringe from the kidney incision site; time to hemostasis was defined as the time elapsed between kidney incision and cessation of observable bleeding or oozing.
Blood samples for determination of apixaban plasma levels and coagulation parameters were collected at baseline, just before 4F-PCC administration (t = 3 min), immediately before kidney incision (t = 8 min), and at the end of the observation period (t = 40 min). Coagulation parameters were assessed as described previously [12] .
Statistical analysis
Mean (SD) or median (range) are reported. Time to hemostasis and blood loss were compared between 4F-PCC-treated and untreated groups using the log-rank test. In vitro coagulation parameters were compared between 4F-PCC-treated and untreated groups in analysis of covariance models. Treatment group was input as the fixed factor, while the value of the coagulation marker at t = 3 min (immediately before 4F-PCC treatment) was the covariate.
Results and discussion
Dose-finding study
In the vehicle control group, a standardized kidney incision led to a median (range) time to hemostasis and total blood loss of 3 (3-5) min and 2 (2-3) mL, respectively. Following i.v. administration of apixaban (800-1600 lg kg À1 ), significant increases were seen in both bleeding endpoints (Fig. 1A) . Maximum bleeding signals were seen at 1200 lg kg
À1
. For this reason, the 1200 lg kg À1 apixaban dose was used to investigate the potential of 4F-PCC to reverse the anticoagulant effects of apixaban. This represents a supratherapeutic dose of apixaban, with the maximal plasma levels, seen at time of 4F-PCC, four-factor prothrombin complex concentrate; IU, international unit. *Vehicle (dimethylacetamide:propanediol:water, 10%:20%:70%) administered. †Isotonic saline 0.9% w/v administered; apixaban/vehicle was administered at t = 0 min, 4F-PCC/saline was administered at t = 3 min. first monitoring (3 min, 1379 ng mL
, Fig. 1B ), corresponding to approximately 4 times the C max seen in healthy volunteers after twice-daily dosing with apixaban 10 mg for 7 days [16, 17] .
Effect of 4F-PCC on apixaban-associated bleeding
Treatment with 4F-PCC at 3 min post apixaban administration led to statistically significant reductions in time to hemostasis compared with saline-treated animals for all doses tested. Significant reductions in total blood loss were also observed for 4F-PCC doses ≥ 12.5 IU kg À1 (Fig. 2) .
Effects of apixaban and 4F-PCC on biomarkers of hemostasis
Modest but dose-dependent increases in PT (1.7-to 2.2-fold), aPTT (2.1-to 2.7-fold), and WBCT (2.1-to 2.7-fold) were observed at 3 min post apixaban treatment (data not shown). Reversal of apixaban-induced PT prolongation with 4F-PCC was partial and significant only with 4F-PCC 12.5, 75, and 100 IU kg À1 (Fig. 3A) , with a maximum reduction of 1.2-fold compared with salinetreated animals seen with 4F-PCC 100 IU kg À1 . The reversal of apixaban-induced WBCT prolongation was also only partial but could be seen for all 4F-PCC doses ≥ 25 IU kg À1 (Fig. 3B) . Compared with saline-treated animals, 4F-PCC 100 IU kg Gray shaded area denotes baseline range for time to hemostasis (3-5 min) in vehicle-treated animals; time to hemostasis > 30 min was not measured and the maximum observation time is denoted by the horizontal dashed line; red shaded area denotes baseline range for blood loss (2-3 mL) in vehicle-treated animals. * and ** indicate statistical significance at the P < 0.05 and P < 0.01 levels, respectively, compared with animals that received apixaban plus saline. 4F-PCC, four-factor prothrombin complex concentrate; IQR, interquartile range; IU, international units.
gation was observed following 4F-PCC treatment (data not shown). Apixaban administration led to nearly full inhibition of extrinsic TG, as indicated by reductions of 42-100% for endogenous thrombin potential (ETP) and 74-99% for peak TG. Subsequent administration of 4F-PCC did not restore either parameter to baseline levels within the dose range tested (Fig. 3C, E) . Conversely, apixaban-induced reductions of TG parameters following intrinsic activation, while less pronounced (17-62% for ETP, 29-47% for peak TG, at t = 3 min), were fully reversed by 4F-PCC. Intrinsic TG was the most sensitive parameter to 4F-PCC-mediated effects on bleeding diathesis, showing statistically significant increases in ETP and peak TG at all 4F-PCC doses tested (Fig. 3D, F) . At 5 min post 4F-PCC dosing, ETP and peak TG were restored to baseline values using 4F-PCC doses as low as 12.5 IU kg À1 (Fig. 3D ) and 6.25 IU kg À1 (Fig. 3F) , respectively. *, **, and *** indicate statistical significance at the P < 0.05, P < 0.01, and P < 0.001 levels, respectively, compared with animals that received apixaban plus saline. 4F-PCC, four-factor prothrombin complex concentrate; ETP, endogenous thrombin potential; IU, international units; PT, prothrombin time; SEM, standard error of the mean; TG, thrombin generation; WBCT, whole blood clotting time.
This study evaluated the potential of 4F-PCC to reverse apixaban-associated anticoagulation in a rabbit model. Blood loss and time to hemostasis following a standardized kidney incision were both markedly increased by i.v. administration of 1200 lg kg À1 apixaban, relative to baseline. Administration of 4F-PCC shortly after apixaban dosing significantly reduced both bleeding time and total blood loss post incision. Notably, these effects were observed at 4F-PCC doses as low as 6.25 IU kg À1 for bleeding time and 12.5 IU kg À1 for blood loss, lower than those required to reverse effects of other NOACs on hemostasis in this model [11] [12] [13] . Reasons underlying this observation, and its clinical relevance, remain unclear.
In the only other published preclinical study of apixabanassociated bleeding reversal, administration of 4F-PCC (Kanokad Ò , LFB, Les Ullis, France) did not reduce hepatosplenic blood loss but restored ETP and thromboelastography parameters in apixaban-treated rabbits [18] . However, baseline bleeding signals in apixaban-treated animals were small (~1.4-fold increase compared with control rabbits) [18] , which may have limited the possibility of detecting the efficacy of potential reversal agents in this model.
Owing to the predictable anticoagulant effects of NOACs, routine anticoagulation monitoring in NOACtreated patients is generally not required [5] , but validated coagulation assays may still be useful in emergency situations. Changes in PT, aPTT, WBCT, and TG were seen following apixaban dosing, in agreement with in vitro studies of apixaban in human plasma [19] and in vivo studies in healthy volunteers [20, 21] . However, there was a lack of robust correlation with 4F-PCC reversal of bleeding diathesis in vivo in this study. Apixaban-induced aPTT prolongation was not reversed by 4F-PCC, and apixaban-induced increases in PT and WBCT were only partially reversed. This disconnect between coagulation parameters and bleeding cessation extends to reversal of other NOACs in preclinical models [11] [12] [13] 18, 22] and clinical situations [10] . Appropriate assays for the monitoring of NOAC reversal therefore still need to be validated.
In this study, the most sensitive in vitro marker of 4F-PCC-mediated reversal of apixaban-associated bleeding was intrinsic TG. Baseline levels were achieved at 4F-PCC doses as low as 12.5 IU kg À1 for ETP and 6.25 IU kg À1 for peak TG, correlating well with the observed reversal of apixaban effects on bleeding time and volume. Similar findings were reported for reversal of rivaroxaban in this animal model [10] . Recent studies of edoxaban reversal in this model [12] and in healthy volunteers using a punch biopsy [23] also confirmed that ETP was a good surrogate biomarker of 4F-PCC's hemostatic efficacy. However, extrinsic TG was used for the edoxaban reversal studies, indicating differential assay responses to 4F-PCC for each FXa inhibitor.
In the current study, overcorrection of ETP was observed when higher doses of 4F-PCC were administered following intrinsic, but not extrinsic, activation. Therefore, the clinical relevance of this overcorrection regarding a possible thromboembolic risk associated with 4F-PCC use for NOAC reversal remains unclear, and future studies of the safety of PCC treatment for NOAC reversal are warranted.
The strengths and limitations of this study should be mentioned. Similar study designs allow comparison of anticoagulant and reversal effects between NOACs using the same 4F-PCC [11] [12] [13] in a model of pharmacologic relevance, owing to the similarity of NOAC anticoagulant effects in rabbits and humans [24] [25] [26] [27] . However, the results of this study following supratherapeutic doses of apixaban may differ to the effects of clinical doses in humans, and our simplified model of a single standardized incision wound may not be reflective of all situations where anticoagulant reversal is required. Furthermore, this preclinical rabbit model may not fully emulate human anticoagulation reversal, and results therefore need to be confirmed in a clinical context. Finally, this study evaluated an off-label use of this 4F-PCC (currently indicated in the European Union for treatment and perioperative prophylaxis of bleeding in acquired deficiency of the prothrombin complex factors or congenital deficiency of any of the vitamin K-dependent coagulation factors [28] ).
In conclusion, this 4F-PCC effectively reduced apixabanassociated bleeding in a rabbit model of acute hemorrhage. These results are broadly consistent with those obtained previously for other NOACs [11] [12] [13] . TG initiated using the RD reagent was the most sensitive assay to 4F-PCCmediated reversal of apixaban effects on bleeding time and volume. However, in light of the variable correlation of laboratory parameters with in vivo measures of hemostasis, there is a clear need for validated assays to guide NOAC anticoagulation reversal. The agreement of the results from this study with those seen for other NOACs in the same model indicates that this 4F-PCC may be an option for the urgent reversal of the anticoagulant effect of NOACs, but clinical data in human patients are required to confirm these results.
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